Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics Inc.'s ficerafusp alfa, a bifunctional antibody, demonstrates significantly higher objective response rates (ORR) compared to established treatments, achieving a meaningful superiority to Keytruda's performance in similar patient populations. The combination of ficerafusp alfa with Keytruda showcases promising survival metrics, with a median progression-free survival (mPFS) of 9.9 months and median overall survival (mOS) of 21.3 months, suggesting enhanced therapeutic efficacy. These favorable clinical outcomes position Bicara Therapeutics favorably within the highly competitive oncology market, indicating potential for substantial growth and value for investors.

Bears say

Bicara Therapeutics reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, highlighting ongoing financial challenges. The company faces multiple risks that could adversely affect its operations, including the potential for negative clinical results with its lead candidate ficerafusp alfa, delays in progressing this therapy into crucial registrational trials, and difficulties in obtaining necessary regulatory approvals. Additionally, the competitive landscape for bispecific therapies further exacerbates concerns, coupled with the potential for long-term dilution of shareholder value.

BCAX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 5 analysts, BCAX has a Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.